Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Kamada ( (IL:KMDA) ) just unveiled an announcement.
On May 5, 2025, Kamada Ltd. announced the launch of a comprehensive post-marketing research program for CYTOGAM®, aimed at generating key data to support its benefits in managing cytomegalovirus (CMV) in solid organ transplantation. The program will involve ten studies in collaboration with leading U.S. physicians, focusing on novel strategies for CMV management, alternative dosing, and potential new applications of CYTOGAM. This initiative underscores Kamada’s commitment to advancing CMV disease management and enhancing the understanding of CYTOGAM’s mechanism of action, potentially increasing its utilization in the coming years.
More about Kamada
Kamada Ltd. is a global biopharmaceutical company specializing in specialty plasma-derived therapies. The company’s portfolio includes FDA-approved products for rare and serious conditions, such as CYTOGAM®, KEDRAB®, GLASSIA®, and others. Kamada focuses on organic growth, business development, plasma collection expansion, and advancing new product candidates.
YTD Price Performance: 12.50%
Average Trading Volume: 208,179
Technical Sentiment Signal: Sell
Current Market Cap: $380M
See more data about KMDA stock on TipRanks’ Stock Analysis page.